Compare BRTX & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRTX | SXTP |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 3.6M |
| IPO Year | 2015 | 2023 |
| Metric | BRTX | SXTP |
|---|---|---|
| Price | $1.52 | $0.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.70 |
| AVG Volume (30 Days) | 22.6K | ★ 305.0K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.77 |
| EPS | ★ N/A | N/A |
| Revenue | $81,000.00 | ★ $1,005,471.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $383.87 | $70.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 65.49 |
| 52 Week Low | $0.14 | $0.34 |
| 52 Week High | $28.99 | $8.62 |
| Indicator | BRTX | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 41.96 | 29.68 |
| Support Level | $1.32 | N/A |
| Resistance Level | $2.93 | $1.01 |
| Average True Range (ATR) | 0.14 | 0.13 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 53.07 | 2.31 |
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.